Sai Life Sciences set to double process R&D capacity with New Hyderabad facility
The new facility will double the company’s Process R&D capacity, while adding new capabilities.
The new facility will double the company’s Process R&D capacity, while adding new capabilities.
The alliance simplifies the process from preclinical research to initial human trials with coordinated project management and a single contact point.
Sai Life Sciences’ investment aligns with its strategy to focus on niche, high-value pharmaceutical segments.
The Peptide Research Center is equipped with automation, robotics, and more. It is designed to support pharmaceutical and biotech innovators with specialized services.